Krystal Biotech, Inc. (KRYS)

Krystal Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	290.52	50.7	-	-	-
Revenue Growth (YoY)	473.02%	-	-	-	-
Cost of Revenue	20.06	3.09	-	-	-
Gross Profit	270.45	47.61	-	-	-
Selling, General & Admin	113.69	98.4	78.84	41.99	15.06
Research & Development	53.57	46.43	42.46	27.88	17.94
Operating Expenses	167.26	144.83	121.3	69.88	33
Operating Income	103.2	-97.23	-121.3	-69.88	-33
Interest Expense	-	-	-	-1.49	-
Interest & Investment Income	29.66	22.62	5.22	0.2	0.83
EBT Excluding Unusual Items	132.86	-74.6	-116.08	-71.17	-32.17
Gain (Loss) on Sale of Assets	-	100	-	-	-
Legal Settlements	-37.5	-12.5	-25	-	-
Pretax Income	95.36	12.9	-139.98	-69.57	-32.17
Income Tax Expense	6.2	1.97	-	-	-
Net Income	89.16	10.93	-139.98	-69.57	-32.17
Net Income to Common	89.16	10.93	-139.98	-69.57	-32.17
Net Income Growth	715.58%	-	-	-	-
Shares Outstanding (Basic)	29	27	25	22	19
Shares Outstanding (Diluted)	30	28	25	22	19
Shares Change (YoY)	7.16%	8.87%	14.85%	18.15%	18.15%
EPS (Basic)	3.12	0.40	-5.49	-3.13	-1.71
EPS (Diluted)	3.00	0.39	-5.49	-3.13	-1.71
EPS Growth	669.23%	-	-	-	-
Free Cash Flow	119.18	-100.6	-153.55	-116.27	-40.93
Free Cash Flow Per Share	4.01	-3.63	-6.02	-5.24	-2.18
Gross Margin	93.09%	93.90%	-	-	-
Operating Margin	35.52%	-191.77%	-	-	-
Profit Margin	30.69%	21.56%	-	-	-
Free Cash Flow Margin	41.02%	-198.43%	-	-	-
EBITDA	105.66	-93.32	-118.65	-67.11	-31.15
EBITDA Margin	36.37%	-184.07%	-	-	-
D&A For EBITDA	2.47	3.91	2.64	2.77	1.85
EBIT	103.2	-97.23	-121.3	-69.88	-33
EBIT Margin	35.52%	-191.77%	-	-	-
Effective Tax Rate	6.50%	15.24%	-	-	-

Updated Feb 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q